Sermorelin vs IGF-1 DES
Comprehensive side-by-side comparison of mechanisms, dosing, side effects, and research
Also: Geref, GRF 1-29
Sermorelin is a 29-amino-acid fragment of human growth hormone-releasing hormone (GHRH), and it is the shortest piece of GHRH that still works fully. It asks the pituitary to make and release its own growth hormone rather than injecting GH itself. It was once an FDA-approved drug for diagnosing and treating growth hormone deficiency in children, but the manufacturer pulled it from the market in 2008, so today it is available mainly through compounding pharmacies for off-label use.
Also: des(1-3)IGF-1, Des(1-3) IGF-I
IGF-1 DES is insulin-like growth factor 1 with its first three amino acids chopped off, leaving a 67-residue peptide. That small cut makes it bind poorly to the IGF binding proteins that normally keep IGF-1 in check, so more of it reaches the receptor and it acts stronger, but shorter. It occurs naturally in small amounts (it was first isolated from human fetal brain tissue) and is sold online as a muscle-building research peptide. There are no human trials of it at all, so everything said about it in people is extrapolation.
Key Comparison Insights
- Both peptides belong to the Growth Hormone category, suggesting similar primary applications.
Detailed Comparison
| Attribute | Sermorelin | IGF-1 DES |
|---|---|---|
| Category | Growth Hormone | Growth Hormone |
| FDA Status | Not FDA Approved | Not FDA Approved |
| Clinical Status | Pre I II III IV FDA | Pre I II III IV FDA |
| Mechanism of Action | Sermorelin copies the first 29 amino acids of natural GHRH and binds the GHRH receptor on the anterior pituitary, which is the body's normal on-switch for growth hormone production. Activating that receptor tells the pituitary to synthesize and release GH in pulses. A useful safety feature falls out of this design: because the pituitary still answers to its own inhibitory hormone somatostatin, the GH rise stays under negative-feedback control, which makes a true overdose of GH much harder to produce than with injected recombinant GH. | Like regular IGF-1, des(1-3)IGF-1 activates the type 1 IGF receptor, a tyrosine kinase receptor closely related to the insulin receptor. That switches on PI3K/Akt and MAPK signalling, which drives cell growth, protein synthesis and glucose uptake. The difference is the binding proteins. In the body almost all IGF-1 rides around bound to IGFBPs, which limit how much can hit the receptor. Removing the N-terminal tripeptide (Gly-Pro-Glu) sharply weakens IGFBP binding while leaving receptor binding intact. In a 1992 JCI study on rat granulosa cells, des(1-3)IGF-1 was about 10 times more potent than intact IGF-1 when binding proteins were present, and roughly equal once they were removed, which shows the extra potency comes from dodging the binding proteins rather than a stronger receptor hit. The trade-off: unbound IGF-1 is cleared fast, so its action is short and local, which is why people inject it into a specific muscle. It also carries IGF-1's insulin-like effect on blood sugar. |
| Common Dosing | 200-500 mcg before bed Once daily, typically before bed | Community-reported 20-100 mcg per day Usually once daily on training days |
| Administration | Subcutaneous injection at bedtime | Intramuscular or subcutaneous injection (community practice); studied by injection in animals only |
| Typical Duration | 3-6 months typical | Community reports describe short cycles of about 4-6 weeks; there is no human data on safe duration |
| Best Time to Take | Before bed (fasted) | Around training, per community practice |
Possible Side Effects May vary by individual |
|
|
| Research Summary | Sermorelin has a real clinical pedigree, unlike many gray-market peptides. The FDA approved it in 1990 as a diagnostic for GH deficiency and in 1997 for treating idiopathic GH deficiency in children with growth failure, after studies showed about six months of daily injections increased GH release and growth velocity. Published work found intravenous sermorelin is a relatively specific test for GH deficiency with few false positives, and once-daily subcutaneous dosing promoted growth in some GH-deficient prepubertal children. Where the evidence gets thin is the popular adult anti-aging use: a 2006 editorial argued sermorelin is a smarter way to address age-related GH decline than recombinant GH, but it openly conceded that few long-term clinical studies exist. The drug was discontinued commercially in 2008 for business reasons, not safety, so current adult use rests on compounded product and limited modern trial data. | The research is old, small, and entirely in cells and animals. Sara, Carlsson-Skwirut and colleagues isolated a truncated variant of IGF-1 from human fetal brain in 1986 (PNAS). In GH-deficient lit/lit mice, Gillespie and colleagues (J Endocrinol, 1990) found that 3 microgram daily injections of des(1-3)IGF-1 increased body length about as much as 30 micrograms of regular IGF-1, confirming its higher potency in a living animal; organ weights (kidney, heart) also rose. Adashi and colleagues (JCI, 1992) showed the roughly 10-fold potency gain disappears when IGF binding proteins are removed. Beyond that, it is mostly a lab tool for studying the IGF system. There are no human trials, no pharmacokinetic data in people, and no safety data. Claims about local muscle hyperplasia, fat loss, or recovery are bodybuilding lore built on IGF-1 biology, not on studies of this peptide. Theoretical risks are the same as for IGF-1 and other analogues: low blood sugar, and long-term concerns about feeding the growth of existing tumours, since IGF-1 signalling is a known growth pathway in several cancers. Quality is another unknown: the material sold online has no pharmaceutical oversight. |
Frequently Asked Questions: Sermorelin vs IGF-1 DES
What is the difference between Sermorelin and IGF-1 DES?
Sermorelin is a growth hormone peptide that sermorelin is a 29-amino-acid fragment of human growth hormone-releasing hormone (ghrh), and it is the shortest piece of ghrh that still works fully. it asks the pituitary to make and release its own growth hormone rather than injecting gh itself. it was once an fda-approved drug for diagnosing and treating growth hormone deficiency in children, but the manufacturer pulled it from the market in 2008, so today it is available mainly through compounding pharmacies for off-label use. IGF-1 DES is a growth hormone peptide that igf-1 des is insulin-like growth factor 1 with its first three amino acids chopped off, leaving a 67-residue peptide. that small cut makes it bind poorly to the igf binding proteins that normally keep igf-1 in check, so more of it reaches the receptor and it acts stronger, but shorter. it occurs naturally in small amounts (it was first isolated from human fetal brain tissue) and is sold online as a muscle-building research peptide. there are no human trials of it at all, so everything said about it in people is extrapolation. The main differences lie in their mechanisms of action and clinical applications.
Which is better, Sermorelin or IGF-1 DES?
Neither is universally "better" - the choice depends on your specific goals. Sermorelin is typically used for growth hormone purposes, while IGF-1 DES is used for growth hormone. Always consult with a healthcare provider to determine which may be appropriate for your situation.
Can Sermorelin and IGF-1 DES be used together?
Some peptide protocols combine multiple compounds for synergistic effects. However, using Sermorelin and IGF-1 DES together should only be considered under medical supervision, as both compounds have their own side effect profiles and potential interactions. Research on their combined use may be limited.